Trials / Completed
CompletedNCT02424682
Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer
Safety of Herceptin in Metastatic Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 69 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to evaluate safety and tolerability of Herceptin as treatment for patients with human epidermal growth factor receptor 2 (HER-2) positive metastatic breast cancer. Frequency, characteristics and severity of adverse events (AE) and serious adverse events (SAE) were followed to evaluate the safety of Herceptin in patients with HER2 positive metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | No intervention administered in this study |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2015-04-23
- Last updated
- 2016-11-02
Locations
1 site across 1 country: Serbia
Source: ClinicalTrials.gov record NCT02424682. Inclusion in this directory is not an endorsement.